Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted…

By H. Rizvi, F. Sánchez-Vega, Konnor C. La, W. Chatila, P. Jonsson, D. Halpenny, A. Plodkowski, N. Long, J. Sauter, N. Rekhtman and 22 more. Journal of Clinical Oncology, 2018

1,176 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/a95d7f09932077ea751e721fdce9bab624909f67

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Oncology

In Pulmonary and Respiratory Medicine

Citations in the corpus

Genomic features of response to combination immunotherapy in patients with advanced non-small cell lung cancer (2018, background): “…advanced NSCLC. Emerging independent sets of data have demonstrated that targeted next-generation sequencing (NGS) panels, which are already being used routinely in clinic, may provide a reasonable estimate of exonic mutation burden (Chalmers et al., 2017; Rizvi et al., 2018; Zehir et al., 2017).”
Acquired Resistance to Immune Checkpoint Inhibitors (2020, background): “4%) patients had biallelic alterations in B2M (Rizvi et al., 2018).”
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic (2018, background): “6% versus 25% [68] NSCLC CM 012 WES 158 mutations 51% versus 13% 17.”
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma (2018, result): “55(0) 30(9) 14(23) 6(30) 2(32) 1(32) 0(33) PD-L1 ≥1% nonsquamous NSCLC”